Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study.

Articolo
Data di Pubblicazione:
2011
Citazione:
Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study / R. E., Nappi; G., Sances; G., Allais; E., Terreno; C., Benedetto; Vaccaro, Valentina; F., Polatti; Facchinetti, Fabio. - In: CONTRACEPTION. - ISSN 0010-7824. - STAMPA. - 83:3(2011), pp. 223-228. [10.1016/j.contraception.2010.07.024]
Abstract:
Migraine with aura (MA) is a contraindication to the use of combined oral contraceptives (COCs) because of the increased risk of ischemic stroke. Progestogen-only contraceptive pill (POP) is a safe alternative to COCs and it is preferable in women with cerebrovascular diseases or risk factors for stroke.Prospective diary-based pilot study. Thirty women with MA (n = 15 who have never used COCs and n = 15 who had previously used COCs were diagnosed according to the International Headache Society criteria. The observational period lasted 9 months during which women filled in a diary with the clinical characteristics of headache attacks. After a 3-month run-in period, each subject received an estrogen-free desogestrel (DSG) (75 mcg/day)-containing OC (Cerazette(®); Schering-Plough, formerly NV Organon, Oss, The Netherlands). Follow-up evaluations were planned at the end of the third and sixth month of treatment.The number (mean±S.D.) of migraine attacks was significantly reduced both in previous COCs users (from 3.9±1.0 to 2.9±0.8; p<.001) and nonusers (from 3.2±0.9 to 2.6±1.3; p<.02) following 6 months of POP use in comparison with the run-in period. Duration of headache pain did not differ significantly in both groups throughout the study. Interestingly enough, a beneficial POP effect on the duration (mean±S.D.) of visual aura (from 16.3±9.5 to 11.4±5.6 min) and on the total duration (mean±S.D.) of neurological symptoms (from 33.6±23.3 to 18.6±18.0 min) was only significantly reported by previous COCs users (p<.001, for both) by the end of the study period. The POP was well tolerated by each woman and the bleeding pattern was variable with a tendency towards infrequent bleeding.The present study supports the use of the POP containing desogestrel in a population of women with MA and underlines a positive effect on symptoms of aura, especially in MA sensitive to previous use of COCs.
Tipologia CRIS:
Articolo su rivista
Keywords:
Adult, Chi-Square Distribution, Contraception; methods, Contraceptives; Oral; administration /&/ dosage, Desogestrel; administration /&/ dosage, Female, Humans, Migraine with Aura; physiopathology, Pilot Projects, Progestins; administration /&/ dosage, Prospective Studies
Elenco autori:
R. E., Nappi; G., Sances; G., Allais; E., Terreno; C., Benedetto; Vaccaro, Valentina; F., Polatti; Facchinetti, Fabio
Autori di Ateneo:
FACCHINETTI Fabio
Link alla scheda completa:
https://iris.unimore.it/handle/11380/709039
Pubblicato in:
CONTRACEPTION
Journal
  • Dati Generali

Dati Generali

URL

http://dx.doi.org/10.1016/j.contraception.2010.07.024
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.0.0